NCT04584008 - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics | Biotech Hunter

Enrollment

600

Participants

Timeline

Start Date

September 23, 2020

Primary Completion Date

November 30, 2024

Study Completion Date

March 31, 2025

Conditions

Biliary Tract NeoplasmsGastric CancerEsophageal Squamous Cell CarcinomaColorectal CancerGastrointestinal Stromal TumorsPancreatic CancerNeuroendocrine TumorsUnknown Primary CancerDigestive Cancer

Interventions

DRUG

FGFR Inhibitor, IDH1 Inhibitor, HER2 Inhibitor, PARP Inhibitor, BRAF Inhibitor, MEK Inhibitor, ICIs, EGFR-TKIs, NTRK-TKI, and et. al.

According to the treatment dose approved by NMPA/FDA, evaluation will be conducted every 2 cycles until tumor progression or adverse events cannot be tolerated.

DRUG

Other Therapy

Patients will receive other treatments, including cytotoxic drugs, antiangiogenic drugs, best supportive care, clinical trials of unmatched new drugs, etc..

Trial Locations (1)

100142

Peking University Cancer Hospital, Beijing